Sharps Technology Implements One-Year Poison Pill with $10 Rights, 15% Trigger
Sharps Technology’s board approved a one-year poison pill issuing one purchase right per share exercisable at $10 if any holder crosses 15%, covering shares outstanding May 26, 2026, expiring May 12, 2027. It blocks hostile accumulations without a control premium and aligns with its Solana SOL treasury strategy.
1. Plan Adoption
Sharps Technology’s board adopted a limited duration stockholder rights plan to protect the company and its stockholders after recent accumulations of common stock. The plan, often called a poison pill, is intended to ensure all shareholders receive fair treatment and value recognition.
2. Plan Mechanics
Each outstanding share as of the close of business on May 26, 2026 will carry one preferred share purchase right exercisable at $10 if any person or group acquires 15% or more of common stock without board approval. Rights will trade with common shares, become exercisable upon a trigger event, expire May 12, 2027, and void for the acquiring party.
3. Strategic Rationale
Executive Chair Paul Danner stated the rights plan is a prudent measure to guard against tactics aimed at gaining control without an appropriate premium. The board retains flexibility to consider any fair proposal and remains focused on executing its transformational strategy to drive long-term shareholder value.
4. Digital Asset Treasury Strategy
In parallel, Sharps Technology continues its digital asset treasury strategy by accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital raises to generate on-chain yield and enhance treasury returns.